- High antibody levels tied to nerve damage in RA
- Helps explain numbness and tingling in patients
- Not a treatment yet — still in early research
This study reveals why some RA patients develop nerve pain — and who’s most at risk.
You wake up with tingling in your hands. It feels like pins and needles. At first, you shake it off. But over time, the numbness spreads. For people with rheumatoid arthritis (RA), this isn’t just discomfort — it could be nerve damage. And until now, doctors haven’t always known why it happens.
We now have a clearer clue.
A new study shows that RA patients with high levels of a specific antibody — called anti-citrullinated peptide antibodies (ACPA) — are far more likely to have peripheral neuropathy (PN). That’s the medical term for nerve damage that causes pain, numbness, or weakness, usually in the hands and feet.
RA affects over 1 million adults in the U.S. alone. Most people think of joint pain and swelling. But RA is more than that. It’s an autoimmune disease — meaning the body’s immune system attacks its own tissues.
And sometimes, it doesn’t stop at joints.
Up to 1 in 3 RA patients may develop nerve problems. Yet these symptoms are often missed. Why? Because they don’t show up on X-rays. And unlike joint pain, nerve damage can be silent at first.
Current treatments focus on reducing inflammation. But they don’t always prevent nerve issues. That leaves patients struggling with symptoms they can’t explain — and doctors without clear answers.
The hidden link
For years, doctors assumed nerve damage in RA was just from long-term inflammation. The longer you had RA, the more likely you were to get PN.
But here’s the twist: this study found something else.
It wasn’t how long someone had RA — or even how bad their joint pain was — that mattered most. Instead, it was their ACPA level.
ACPA is a blood marker already used to diagnose RA. But now, it may do more than confirm disease — it could predict who’s at risk for nerve damage.
What scientists didn’t expect
Patients with PN had significantly higher ACPA levels than those without. In fact, the odds of having nerve damage were over 7 times higher in people with elevated ACPA.
That’s a strong link.
And CRP — another marker of inflammation — didn’t show the same connection. This suggests nerve damage in RA may not just be from swelling. It could be directly tied to how the immune system misfires.
Think of ACPA like a “wanted” poster the immune system creates. It tells immune cells to attack certain proteins in the body. But sometimes, those proteins are also found in nerves. So the attack spreads — like friendly fire.
The surprising shift
This changes how we think about RA. It’s not just a joint disease. It’s a whole-body condition that can reach the nervous system — and ACPA might be the red flag that shows who’s most vulnerable.
Imagine your nerves are like electrical wires. They send signals from your brain to your hands and feet. But in PN, those wires get damaged — like frayed cords.
The body’s immune system, meant to protect, starts attacking the insulation around these wires. ACPA appears to play a role in turning that attack on.
High ACPA levels may mean the immune system is more aggressive — not just in joints, but in nerves too.
Researchers looked at 63 RA patients. Eighteen had nerve damage confirmed by a test called electroneuromyogram (ENMG). The rest did not. Blood tests checked for ACPA, rheumatoid factor (RF), and CRP. They compared the two groups to see what stood out.
The biggest difference? ACPA.
Patients with high ACPA were much more likely to have PN. The link was so strong, it stood out even after accounting for age, disease duration, and other factors.
And it wasn’t about symptoms. Some patients had nerve damage on tests — but no pain or numbness. That means damage could be starting long before anyone notices.
This doesn’t mean this treatment is available yet.
But there’s a catch.
The study didn’t prove that ACPA causes nerve damage — only that it’s strongly linked. It’s possible both are driven by another hidden factor.
Also, the study was small. Just 63 people. And it looked at patients at one point in time — not over years. So we can’t say for sure if high ACPA leads to PN down the road.
This fits with growing evidence that ACPA isn’t just a marker — it may actively harm tissues. Some lab studies show these antibodies can bind to nerve cells. That raises the possibility they’re not just bystanders, but players in nerve damage.
If you have RA and notice tingling, burning, or numbness — especially in your hands or feet — talk to your doctor. Ask if nerve testing might help.
This study doesn’t change treatment today. But it could shape the future. One day, checking ACPA levels might help doctors spot nerve risks early — and act before damage sets in.
For now, the best defense is awareness.
Larger, long-term studies are needed to confirm these findings. Researchers will need to track patients over time to see if high ACPA truly predicts nerve damage. If so, new treatments could one day target ACPA directly — not just inflammation. But that’s still years away. Science moves slowly, but each clue brings us closer.
